Tag Archive for: partnership

Lonza's Visp manufacturing site, eight months ago. © Lonza

Asher Biotherapeutics Inc has expanded its manufacturing agreement with Lonza to include the manufacturing of AB248.

Lung cancer cells. © Evotec SE

Evotec SE and Janssen Biotech Inc have agreed to co-develop targeted immuno-oncological therapies.

© Synaffix BV

Rational antibody design specialist Hummingbird Bioscience has licenced a cancer target and the modular ADC technology of Dutch Synaffix BV.

© Ethris GmbH

Cipla EU Ltd is going to make an equity investment of €15m in Ethris GmbH, a specialist for respiratory  delivery of therapeutic mRNAs.

© fernandozhiminaicela/pixabay.com

CEPI fights the betacoronaviruses by funding Ethris GmbH and DIOSynVax Ltd and their joint effort to advance their work on an mRNA vaccine.

Ryvu Lab in Krakow, Poland ©Ryvu Therapeutics SA

Renewed focus on cancer: COVID-19 vaccine company BioNTech SE (Nasdaq: BNTX) and Ryvu Therapeutics S.A., located in Krakow (Warsaw Stock Exchange: RVU), a Polish clinical-stage cancer therapeutics development company, announced that the companies have entered into a research collaboration for several multi-target immunotherapy programmes, as well as an exclusive licensing agreement for Ryvu’s STING agonist portfolio as stand-alone small molecules.

Differencesto conventional ADCs reported on LegoChem Biosciences's homepage. © LegoChem Biosciences

SOTIO Biotech a.s. has exercised its first of five exclusive, target-specific options for antibody-drug conjugate (ADC) SOT106 under its agreement with LegoChem Biosciences Inc.

AstraZeneca headquarters at Cambridge. 
© AstraZeneca  plc

C4X Discovery Holdings plc has exclusively licenced its NRF2 Activator programme to AstraZeneca and has got an upfront payment of $2m.

© PublicDomainPictures/pixabay.com

Microbial casein maker Standing Ovation SA has inked an exklusive collaboration with Bel Group, one of France’s biggest cheese-makers to bring its vegan cheese to the market.

Memo Therapeutics used its huMemoMAB platform to develop antibodies to treat cancers and infections. © Memo Therapeutics AG

Antibody developer Memo Therapeutics AG has snaged a R&D partnership with Ono Pharmaceutical Co. Ltd in the immuno-oncology field.